you. Thank
afternoon. Good
for quarter everyone for Fate the And financial joining results second XXXX call. Therapeutics thanks us
Shortly after X p.m.
the section Eastern Time Press which on results, release Releases. with & today, we issued can a be site our Web of press these Investors under Media found
filed the site In was Investors section our XX-Q Web & Financial XX, Form can Information. and our the quarter Media thereafter addition, June be under ended for XXXX, shortly found on of
except this for I'd statements under like to are of that Securities Reform provisions facts, and remind Before the forward-looking Harbor of we the Litigation statements everyone Act made responses begin, historical to conference statements management XXXX. by of Safe Private questions the on call
the results statements. from in company's the These Form as close statements involve the see risks Please was the earnings our after and disclaimer in actual XXXX, the XX, as differ of filed such company's press today, included those to that with risk uncertainties SEC on market forward-looking forward-looking XX-Q ended factors June cause today. filings, that in well quarter statement the issued the for release materially can SEC
disclaims information, not reflect date obligation and forward-looking to speak statements, on circumstances. placed as of any to change. Except the statements only may statements update or forward-looking future law, the should forward-looking Therapeutics circumstances by reliance they Undue Fate as be made these these are which facts events underlying required as
and the a safety of cell product derived paradigm technology. a Dr. an treatment February XXXX, in Fate of to a stem clinical tolerability is first first is or Joining from a of class trial patient therapy. an ever derived is the multi-dose the study Dan evaluate induced our iPS In United trial and in cell It or investigate a The cells novel today's the Officer. brand-new Therapeutics cell treatment me Shoemaker, of cell States it multiple, on is the iPSC to iPS derived pluripotent the products call landmark in Chief therapy is initiated first Scientific field clinical to administered cycles.
FTXXX and United investigation iPSC for product is iPSC line off master this derived cell master the which has numerous manufacture FTXXX in cancer of of a begin the the in overcome require therapy, batch first is from by cell brand-new a clinical States, cell shelf to engineering clonal cell use universal products line. for the cells, NK sourcing class to repeated immunotherapy a The manufacture. patient the of of donor the limitations batch inherent potential source in clonal and
cost-effective master a renewable uniform contrast, and source in lines products produced in which for at can manner to well be delivered mass significant In and cell are on demand scale are composition, clonal defined be cell can patients. manufacturing iPSC
believe clinical therapies T-cell and multi-cycle Most patients We the therapies to benefit potential has the CAR therapeutic therapy. are treatments source products often FTXXX cell the conveyed treatment a too ever we multi-dose, In patient short of derived single administrating trial, feasibility first are the cell investigating emerging cell field the on including schedule. to this iPS be of class of administration revolutionize lived. donor and can
that including and action. field established immunotherapy, to of cell-based the have such therapeutic dosing. be cycle paradigm demand, the can at products uniquely of per with in multi exists treatment more synergistic optimize multi-dose, multi-dose, complementary treatment to cancer cell we products. multi-cycle such on cell dose, opportunity cost continuous with exposure agents derived over a convey iPS believe potential And cryo-preserved responses delivered weeks paradigm provide Since has may patients repeat months and In the mass produced durable and a therapeutic mechanisms low for combination
to The weekly trial FTXXX therapy to as on doses inhibitor tumors Patients a additional initial label once failed in as therapy. trial designed once activity of combination patients in monotherapy of who approved clinically of checkpoint second an FTXXX whose FTXXX with escalating who progressed patients doses. safety tumors for advanced a three a treatment therapies. of and and assess of treatment The is or respond weekly first three have the following open solid all X dose the Phase clinical are are stable failed inhibitor study checkpoint treatment cycle clinical following to response eligible cycle is the receive
a the arm. level and All of at doses FTXXX that in no an the with In eligible outpatient first May the received serious cells Cell XXX cells three in three Gene per of treatment once tolerated XXXX, of treated Society we dose setting were toxicities the FTXXX Therapy, per and FTXXX-related dose. monotherapy each which million patients in second studies FTXXX weekly cycle treatment the events. limiting patients multi-dose XXX receive well cycle, three announced at first with of dose no All three at were American first was to dose million patients adverse
million have FTXXX patients six the with combination related serious FTXXX level monotherapy with immune first of I dose three and arm am limiting each with received no per FTXXX six treated additional cycle. these treated additional and studies patients In these pleased the in three receive per toxicities adverse FTXXX in six to FTXXX, additional at All of second additional first setting dose of a of to patients with treated dose announce well an level outpatient were eligible in weekly once were patients, no of now at of XXX cycle. million the dose that patients was with in dose six patients events. All treatment second cells we cells the checkpoint studies XXX multi-dose three doses FTXXX treatment the tolerated inhibitor. arm each these were
receiving have investigators reported events patients serious no FTXXX-related adverse by dose limiting been in no To-date toxicities and FTXXX.
the schedule. observations is brand-new of FTXXX these a We FTXXX derived a class treatment encouraged multi-cycle is on given first products administered that initial iPS being multi-dose, cell in and safety are very by
products for patient's dose or changes by the FTXXX cells potential of T iPS of of integral clinical cytokine administered this T immunogenicity activation levels patient's derived conducting as This our the including measuring K cell immune the cells, and patient's the we are the of cells demonstrate robust FTXXX T part cycle, course CDX cells of patient's mediated the the further B program. treatment development To and over including assessment and evaluating immunological an assessment profile a regulatory profiling cells. potential on cells includes anti-cell durability in
provide FTXXX of including the study activity XXXX. immunological the and update efficacy data expect an safety, on in to We second half
is FTXXX platform. first for receptor. is our I pleased initiating engineered in to the Fc express iPSC candidate universal world CDXX clonal hnCDXX our a to am that clinical non-cleavable of a and K or second derived be proprietary off investigation now the and the clinical product are product product it targeted shelf high-affinity from a cleared iPSC derived candidate announce novel from to engineered FTXXX, cell also clonal investigation emerging cell line product iPSC we our master line master from
against vial bag cell FTXXX was for single the and We engineered bank and including master identity, CGMP post-thaw tested and The of cryo-preserved from iPSC doses testing viability clinical campaign. initiation. a cryo-preserved release functional production completed with activity. GMP hundreds ready Starting single FTXXX clonal product have of final were a an product infusion a product in was cryo-preserved cell specifications stringent purity, in manufactured of
safety are refractory which concurrently million, following second and trial trial label additional FTXXX. dose. refractory activity for enroll escalating directed Both will assess doses cell with in clinical lymphoma. once cycle FTXXX the is is stable myeloid across dose study clinical acute arms as of Phase weekly eligible X CDXX dose a an of of XX and B three therapy receive The and is as per for clinically three million treatment are treatment cells relapsed a a planned three levels monoclonal designed monotherapy treatment to the million the treatment antibody XXX leukemia open of who of to FTXXX the XXX of being cycle once doses. study investigated The combination first relapsed of Patients weekly the
CDXX dose a single include at cells initial patient XX per of million will combination escalation enrollment Specific dose. with an therapy, to antibody monoclonal directed
patient currently working are We We believe to FTXXX. the initiate is United enrollment. five there support compelling with clinical precedent to States clinical benefit sites in of therapeutic the
we believe are of assess Additionally, there we benchmarks the which and against can safety FTXXX. well-established efficacy clinical
been AML, cells or release NK derived associated relapsed cell refractory graft-versus-host patients derived of not Notably therapy. In hundreds of treated syndrome with cytokine with NK been have the donor have disease. donor setting
remission in be rates from particularly Additionally, marrow reported studies. have having leukemic cell NK been blast direct complete bone the mediated to to been XX% killing susceptible shown with to in ranging investigator-initiated XX%
to the first perform biopsies to activity. treatment in following bone treatment the post FTXXX FTXXX third insights cycle marrow gain into of additional plan We that dose
Additionally, anti-tumor CDXX potent coated which bind the approved antibody studies mechanism targeting cells by monoclonal dependent ADCC, a antibody of therapy recognized, kill of demonstrated numerous importance have tumor cytotoxicity clinical cellular FDA cancer or NK expressing antibody and cells.
high-affinity binding variant surface have significantly FTXXX have monoclonal XXXV, XXXV, only from all which antibodies shown for tumor-targeted XX% to which with studies antibody hnCDXX CDXX patients the present Fc for expect ADCC. following the CDXX is of augment because improved levels outcomes expression Consequently, a incorporates also in receptor, homozygous therapy. variant that active to novel high-affinity about FTXXX we Clinical patients of treatment enhanced maintains clinical of
complete of monoclonal overall approximately for relapsed As of approximately antibody directed with rates lymphoma, enhanced CDXX X% patients and a agent rates demonstrated XX%. refractory response ADCC and therapies have benchmark response single B-cell
including second and XXXX. on provide patients of We the the update activity expect an efficacy in safety, immunological data first the from study FTXXX half to
The leukemia the immunotherapies with tumor generation to experience those therapy. a limitation respond. patient response clinical Clinical that CAR both and antigen patients single that are of specifically have targeted toward of next in moving are clearly CDXX cancer and And patients of T cells for initially lymphoma associated all we even not case wave cells myeloma cell-based engage that derived designed development first respond T in and against CAR antigens. demonstrated of multiple against BCMA remains significant durability
than incorporating Among target antigen to due the tumor To antigen more cells. limitation, mitigate mechanisms the the reduce one are risk to and relapse antigen cancer simultaneously immunotherapies of is escape. loss regulation of this from generation next identified target relapse disease or earliest of strategies down
the engagement shelf last off and days, CAR new we company's am FTXXX candidate NK universal within first to emerging to for master [validity] our a line iPSC the Drug receptor drug clonal monoclonal antigens application [ph]. potent CAR investigational engineered of with CDXX, product three from submitted Administration tumor proprietary pleased for and and the a IL-XX that with from an candidate associated I modalities, additional combination therapy is novel proliferative capacity the XX derived fusion NK a product antibody functional a third improved announce U.S. is iPSC FTXXX, Food and the cell functional in unique product distinct receptor platform. for targeting cell hnCDXX
additional B-cell naturally cancer recognizing locus to and expresses the activating malignancies. potential D significantly believe receptors to disrupt a cancer other killing CAR allogeneic immunotherapy has to be We FTXXX NKG to as XX And landscape. such best-in-class cells. Moreover, T alpha the function and immune cell-based FTXXX of in convey treatment that for cell innate the
treatment to by showed multiple reported candidate. designed cell antigens and derived to in CAR multiple Anderson, safety the potential been CAR CAR FTXXX and cord doses XX-day clinical Furthermore, NK shelf engage a cells approved over administered has profile. which tumor universal XX It blood cells the substantially malignancies data it be comparable off T product investigators currently NK MD response with to to XX multiple specifically supportive cell patients with delivered therapies have rates from B-cell clinical XX of improved is is cycles. associated a
of a as cell The leukemia. submitted with monotherapy in lymphocytic to monoclonal FDA was as FTXXX lymphomas CDXX refractory the clinical centers. relapsed investigate for several to clinical leading antibody with combination therapy advanced chronic and treatment protocol a CAR the and B-cell investigators FTXXX at consultation for directed medical developed T intend We
FTXXX administer treatment multi-cycle to cycle. a using plan conclusion initial each response assessments We at schedule and to multi-dose, the conduct of treatment
our Kettering of under the therapy and the Dr. of cancer cell with development cell we franchise, T to development T by in CAR clinical NK assert IPS derived our Michelle cell exclusive position the immunotherapy derived Sloan continue leadership collaboration Memorial off our research Alongside shelf Sadelain. iPS led
the targeting expression cell off cell the shelf into a receptor of a derived FTXXX discovered having construct including receptor first Our candidate the and and clonal cell FTXXX T incorporates of T car CAR locus. design novel Dr. a universal engineered by master cell Sadelain. complete elimination T for iPSC products CDXX T of from product CAR insertion line best-in-class alpha Xxx use components attributes We CAR believe is
initiated We Memorial transfer drug protocols manufacturing production support in GMP Sloan application compliant technology initiation an for have to Kettering our differentiation of the submission. team now pilot new investigational of of at
We iPS an renewed collaboration derived for candidates company's Dr. additional of the three also development the years. product with research for and have exclusive T cell Sadelain
having to Additionally, therapy to out. is I Genomic Engineering knocked a cell life-threatening of note off CAR T-cell encoded Cells elimination The iPSCs and endogenous to CAR a of derived Office gene ensure T construct company occur a patent track the am XXXXXXXX critical iPS therapy. disease, pleased the Pluripotent when Number locus Patent recently endogenous Patent U.S. alpha in disease that can of covers U.S. complete entitled patient's granted T-cells gene the an of the foundational Trademark shelf donor attack compositions CAR TCR healthy a into to prevention that tissue. allogeneic graft-versus-host the and TCR the
Importantly, not to is associated limited locus encoded into antigen. the tumor TRAC specific the CAR construct a
over clinical regulatory Finally, our advanced quality have development. as iPSC which thank into at has significantly teams Therapeutics, platform months product Fate and the I past want manufacturing proprietary XX expanded to the
of In to clinical XXXX IND, anticipate cell GMP shelf remains product their the role on-time the fall of candidates. manufacturing schedule supply derived in-house on of in of launch our production in GMP of our the our the addition FTXXX off for and initiation facility we instrumental iPS submission in-house
Turning common $XX.X $X.XX or for share share last financial period common Fate million a of ended net XXXX, second or compared the year. a net of $X.XX million to as quarter for our same results, incurred June loss XX, the $XX.X to Therapeutics per per loss
from $X quarter with the compared collaboration primarily for of Revenue Pharmaceutical. ONO Revenue million was the XXXX XXXX. for was $X.X second derived second of the to million quarter company's
of development associated million period the share-based the for of to and with with collaboration increase our $XX.X XXXX the associated under headcount advancement and pipeline, $XX.X the last growth in in to research RD for development company's including associated activities and expenses expenses was of with primarily product million compensation company's Research compensation an quarter expenses manufacture employee the candidates attributable support clinical the the second the were conduct increase our of to compared with Pharmaceutical. year. The expenses our product ONO in same
year. $X.X G&A expenses for for the period second quarter of XXXX an were $X.X including our the primarily million compared last compensation, million in compensation. employee was G&A share-based to in increase to increase The expenses same attributable
shares preferred which into convertible common five of million. $XXX each of was of were net expense convertible Our quarter shares short-term was of compensation shares of cash under for $X.X and the certain total approximately the second million operating conditions. quarter At expenses XXXX, X.X investments stock-based non-cash million and of were second Common the stock stock end $XX.X million is XXXX, million. XX.X equivalents outstanding cash, outstanding of stock
And call I'd open questions. up to with the that, any to like
